CN119522097A - 5t4抗体-药物缀合物及其用途 - Google Patents
5t4抗体-药物缀合物及其用途 Download PDFInfo
- Publication number
- CN119522097A CN119522097A CN202380052757.2A CN202380052757A CN119522097A CN 119522097 A CN119522097 A CN 119522097A CN 202380052757 A CN202380052757 A CN 202380052757A CN 119522097 A CN119522097 A CN 119522097A
- Authority
- CN
- China
- Prior art keywords
- amino acid
- acid sequence
- seq
- substituted
- adc
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
- A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
- A61K47/68033—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a maytansine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
- A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202510757191.4A CN120571033A (zh) | 2022-05-13 | 2023-05-10 | 5t4抗体-药物缀合物及其用途 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202263341957P | 2022-05-13 | 2022-05-13 | |
| US63/341,957 | 2022-05-13 | ||
| PCT/US2023/066811 WO2023220620A2 (en) | 2022-05-13 | 2023-05-10 | 5t4 antibody-drug conjugates and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510757191.4A Division CN120571033A (zh) | 2022-05-13 | 2023-05-10 | 5t4抗体-药物缀合物及其用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN119522097A true CN119522097A (zh) | 2025-02-25 |
Family
ID=88731090
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202380052757.2A Pending CN119522097A (zh) | 2022-05-13 | 2023-05-10 | 5t4抗体-药物缀合物及其用途 |
| CN202510757191.4A Pending CN120571033A (zh) | 2022-05-13 | 2023-05-10 | 5t4抗体-药物缀合物及其用途 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202510757191.4A Pending CN120571033A (zh) | 2022-05-13 | 2023-05-10 | 5t4抗体-药物缀合物及其用途 |
Country Status (16)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20250060248A (ko) * | 2022-09-07 | 2025-05-07 | 엑셀리시스, 인코포레이티드 | 조직 인자 항체-약물 접합체 및 이의 용도 |
| KR20260114567A (ko) * | 2023-11-15 | 2026-07-22 | 엑셀리시스, 인코포레이티드 | 5t4 항체 약물 접합체 및 이의 사용 방법 |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2020006010A (es) * | 2017-12-11 | 2020-10-16 | Triphase Res And Development Iii Corp | Conjugados de anticuerpo anti-cd22-maitansina, combinaciones y metodos de uso de los mismos. |
-
2023
- 2023-05-10 US US18/863,572 patent/US20250295803A1/en active Pending
- 2023-05-10 CR CR20240491A patent/CR20240491A/es unknown
- 2023-05-10 EP EP23804470.5A patent/EP4522157A2/en active Pending
- 2023-05-10 TW TW112117410A patent/TW202408585A/zh unknown
- 2023-05-10 IL IL316790A patent/IL316790A/en unknown
- 2023-05-10 KR KR1020247040730A patent/KR20250024875A/ko active Pending
- 2023-05-10 CN CN202380052757.2A patent/CN119522097A/zh active Pending
- 2023-05-10 CN CN202510757191.4A patent/CN120571033A/zh active Pending
- 2023-05-10 AU AU2023268538A patent/AU2023268538A1/en active Pending
- 2023-05-10 CA CA3252237A patent/CA3252237A1/en active Pending
- 2023-05-10 PE PE2024002516A patent/PE20251184A1/es unknown
- 2023-05-10 WO PCT/US2023/066811 patent/WO2023220620A2/en not_active Ceased
- 2023-05-10 JP JP2024566281A patent/JP2025516569A/ja active Pending
-
2024
- 2024-11-08 MX MX2024013869A patent/MX2024013869A/es unknown
- 2024-11-11 DO DO2024000233A patent/DOP2024000233A/es unknown
- 2024-11-11 CL CL2024003441A patent/CL2024003441A1/es unknown
- 2024-11-12 CO CONC2024/0015381A patent/CO2024015381A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| TW202408585A (zh) | 2024-03-01 |
| PE20251184A1 (es) | 2025-04-23 |
| US20250295803A1 (en) | 2025-09-25 |
| WO2023220620A3 (en) | 2023-12-14 |
| CA3252237A1 (en) | 2023-11-16 |
| CR20240491A (es) | 2025-01-07 |
| KR20250024875A (ko) | 2025-02-19 |
| CO2024015381A2 (es) | 2025-02-24 |
| CN120571033A (zh) | 2025-09-02 |
| WO2023220620A2 (en) | 2023-11-16 |
| CL2024003441A1 (es) | 2025-02-28 |
| DOP2024000233A (es) | 2025-02-28 |
| MX2024013869A (es) | 2024-12-06 |
| IL316790A (en) | 2025-01-01 |
| JP2025516569A (ja) | 2025-05-30 |
| EP4522157A2 (en) | 2025-03-19 |
| AU2023268538A1 (en) | 2024-11-21 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TW202241521A (zh) | 生物活性物偶聯物及其製備方法和用途 | |
| CN114269389B (zh) | 靶向紧密连接蛋白18.2的抗体药物偶联物 | |
| WO2019170131A1 (zh) | 靶向cd73的抗体及抗体-药物偶联物、其制备方法和用途 | |
| CN104936621A (zh) | 抗IL-13受体α2抗体和抗体-药物缀合物 | |
| EP4603109A1 (en) | Antibody-drug conjugate, preparation method therefor, and use thereof | |
| KR20160113623A (ko) | 항체-약물 접합체 및 면역독소 | |
| CN114127117B (zh) | 用于偶联的多肽复合物及其应用 | |
| WO2024109944A1 (zh) | 抗liv-1抗体、其药物偶联物及其医药用途 | |
| CN115368461A (zh) | 抗trop-2抗体、其抗体-药物偶联物及其医药用途 | |
| CN120571033A (zh) | 5t4抗体-药物缀合物及其用途 | |
| TW202545993A (zh) | 抗dll3抗體、核酸分子、載體、細胞、藥物綴合物或融合蛋白及其用途 | |
| KR20240040098A (ko) | 넥틴-4에 특이적인 항체 및 항체 접합체 및 이의 사용방법 | |
| CN116568707A (zh) | 一种抗体药物偶联物及其医药用途 | |
| CN114652853A (zh) | 抗il-4r抗体-药物偶联物及医药用途 | |
| CN120129535A (zh) | 组织因子抗体-药物缀合物及其用途 | |
| WO2023046003A1 (zh) | 抗体药物偶联物及其制备方法和医药用途 | |
| WO2026021443A1 (en) | Antibody-drug conjugates targeting cdh3 and preparation methods and uses thereof | |
| CN121752598A (zh) | 酪氨酸蛋白激酶膜受体1 (ror1)抗体-药物缀合物和其用途 | |
| HK40129540A (en) | Cdh17-targeting antibody and adc and use thereof | |
| WO2025261511A1 (zh) | 靶向cdh17的抗体和adc及其应用 | |
| HK40079580B (en) | Bioactive substance conjugate, preparation method therefor and use thereof | |
| HK40121296A (en) | Bioactive conjugate, and preparation method therefor and use thereof | |
| CN118119644A (zh) | 具有人源化框架区的抗体 | |
| CN118043328A (zh) | 对nectin-4特异性的抗体和抗体缀合物及其使用方法 | |
| CN120282965A (zh) | 黏蛋白-1特异性抗体缀合物及其使用方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |